Přejít na obsah
ABBVABBV
Zpět na vyhledávání
ABBV
ABBVNYSE

AbbVie Inc.

Healthcare•United States
282,03 US$
-3,98 US$ (-1,39 %)

Tažením v grafu vyberte úsek a zobrazí se procentuální změna.Tažením dvěma prsty vyberte úsek a zobrazí se procentuální změna.

Kapitálová struktura

Tržní kapitalizace
498,52 mld. US$
Enterprise Value
576,14 mld. US$
Hotovost
10,77 mld. US$
Celkový dluh
81,32 mld. US$
Čistý dluh
70,54 mld. US$

Valuace (TTM)

P/E
48,46×
P/E (fwd)
17,39×
P/FCF
26,42×
FCF výnos
3,79 %
EV/EBITDA
18,09×
P/S
—
P/B
—
Beta
0,19

Marže (TTM)

Hrubá marže
73,72 %
EBITDA marže
48,25 %
Provozní marže
36,64 %
Čistá marže
15,67 %
FCF marže
28,59 %

Ziskovost a růst

ROE (rentabilita kapitálu)
—
Růst tržeb (YoY)
10,30 %
Růst zisku (YoY)
2 282,10 %

Dividenda

Dividendový výnos
2,42 %
Roční dividenda
6,92 US$
Výplatní poměr
117,35 %
Datum ex-dividendy
2027-01-15

52týdenní rozpětí

190,75 US$302,93 US$
Aktuální
282,03 US$
Pozice v pásmu
81 %
Nad ročním minimem
+47,85 %
Pod ročním maximem
-6,90 %

Cena v kontextu

-4,41 %od historického maxima
Historické maximum
295,03 US$
Datum maxima
13. 11. 2026
Zpět na maximum
+4,61 %
200denní průměr
241,78 US$
Odchylka od průměru
+16,65 %

O společnosti

Web

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Vedení společnosti

Mr. Robert A. Michael CPA
Generální ředitel (CEO)
  • Mr. Scott T. ReentsExecutive VP & CFO
  • Dr. Azita Saleki Ph.D.Executive VP & COO
  • Dr. Roopal B. Thakkar M.D.Executive VP of Research & Development and Chief Scientific Officer
  • Mr. Jeffrey Ryan StewartExecutive VP & Chief Commercial Officer
  • Ms. Linda RaySenior VP & Chief Information Officer
  • Ms. Elizabeth SheaSenior Vice President of Investor Relations
  • Mr. Perry C. SiatisExecutive VP, General Counsel & Secretary
  • Mr. Demetris D. CrumExecutive VP & Chief Human Resources Officer
  • Mr. Wulff-Erik von BorckeSenior VP & President of Oncology